The Anglo-Swedish pharmaceutical company AstraZeneca and the world's largest generic manufacturer Teva have their patent dispute over the asthma medicine Pulmicort settled.
As the two companies announced on Tuesday, Teva has the unlawful sale of its Nachahmerprodukts in the United States acknowledged. Accordingly, the Israeli group's distribution of its generic agent until mid-December 2009 initially set. Teva then have the exclusive right to sell product again. Already on the U.S. market means Teva may still be sold. According to the agreement pays of generic manufacturers, AstraZeneca also a compensation. The volume, the company not to.
AstraZeneca had after the introduction of cheaper Teva means a profit warning. The pharmaceutical company now confirmed on Tuesday its forecast for the current year and expects to continue with an earnings per share from 4.90 to 5.05 dollars.
As the two companies announced on Tuesday, Teva has the unlawful sale of its Nachahmerprodukts in the United States acknowledged. Accordingly, the Israeli group's distribution of its generic agent until mid-December 2009 initially set. Teva then have the exclusive right to sell product again. Already on the U.S. market means Teva may still be sold. According to the agreement pays of generic manufacturers, AstraZeneca also a compensation. The volume, the company not to.
AstraZeneca had after the introduction of cheaper Teva means a profit warning. The pharmaceutical company now confirmed on Tuesday its forecast for the current year and expects to continue with an earnings per share from 4.90 to 5.05 dollars.
No comments:
Post a Comment